Fig. 3: Dysfunction and recovery of TEBVs by eLDL and/or TNFα exposure.
From: Modeling early stage atherosclerosis in a primary human vascular microphysiological system
a Timeline of TEBV treatment. b Burst pressure (i) and UTS (ii) of TEBVs after 96 h eLDL ± 8 h TNFα exposure (mean ± S.D., n = 3 TEBVs for +/+ and n = 4 TEBVs for others). c (i) Vasoactivity for perfusion without treatment. (ii) Vasoactivity for perfusion with 50 μg/ml eLDL followed by 8 days of recovery without eLDL in perfusion media (mean ± S.D., n = 4 TEBVs, Phe: *P = 0.0335; Ach: *P = 0.028053; **P = 0.006529 compared to before treatment by two-way ANOVA and Tukey post hoc test). (iii) Vasoactivity for perfusion for 8 h with 50 U/ml TNFα exposure followed by 8 days of recovery without TNFα (mean ± S.D., n = 4 TEBVs, Phe: **P = 0.00246, ***P < 0.0001; Ach: **P = 0.0049, ***P = 0.0041; Ach **P = 0.0049, compared to before treatment by two-way ANOVA and Tukey post hoc test). (iv) Vasoactivity for perfusion with 50 μg/ml eLDL for 96 h and 50 U/ml TNFα for 8 h and 8 days of recovery (mean ± S.D., n = 4 TEBVs, Phe:**P = 0.0081; Ach **P = 0.0065 compared to before treatment by two-way ANOVA and Tukey post hoc test). Phe: phenylephrine, Ach: acetylcholine (c). d Normalized NO production (total nitrate and nitrite concentration in media) of TEBVs with no treatment (i), 96 h of eLDL (ii), 8 h of TNFα (iii), 96 h eLDL + 8 h TNFα (iv) exposure and 8 days of recovery (n = 2 from 8 TEBVs).
